Table 2.
Measures of VLA-4 expression and function, and immunophenotype in 175 adult patients with previously untreated AML
| Measure of expression or function | No. | Median or % | Range |
|---|---|---|---|
| α4 | |||
| % expression | 175 | 68.7% | 5.4-99.7% |
| MFI | 175 | 43.4 | 12.2-999.1 |
| β1 | |||
| % expression | 175 | 34.8% | 0.2-99.2% |
| MFI | 175 | 31.6 | 5.9-539.7 |
| Activated expression before 8a2 | 24 | 7.6% | 1.8-30.2% |
| Activated expression after 8a2 | 24 | 10.3% | 3.8-39.2% |
| % of maximum activation | 24 | 69.5% | 6.0-100.0% |
| Soluble VCAM-1 binding | |||
| % binding | 102 | 20.5% | 2.0-96.8% |
| MFI | 102 | 53.2 | 10.4-520.1 |
| Fibronectin adhesion: adherent cell number number | 20 | 110 | 0-1922 |
| VLA-4 message: 104 RNA molecules/μg | 23 | 2.06 | 0.98-3.38 |
| CD34 | |||
| % expression | 175 | 8.0% | 0.2-90.4% |
| MFI | 175 | 33.0 | 7.2-94.7 |
| CD117 | |||
| % expression | 175 | 1.4% | 0.0-63.0% |
| MFI | 175 | 9.0 | 0.0-86.7 |